Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
Merck Sharp & Dohme LLC
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.
Ohio State University Comprehensive Cancer Center
CSPC Ouyi Pharmaceutical Co., Ltd.
University of Chicago
University of Chicago
The Christie NHS Foundation Trust
University of Pisa
Leaf Vertical Inc.
National Cancer Institute (NCI)
Galectin Therapeutics Inc.
Mayo Clinic
National Cancer Institute (NCI)
Peking University
Alliance for Clinical Trials in Oncology
Stanford University
National Institutes of Health Clinical Center (CC)
Simcere Pharmaceutical Co., Ltd